Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study

Fallowfield, L.; Osborne, S.; Langridge, C.; Monson, K.; Kilkerr, J.; Jenkins, V.

doi:10.1016/j.breast.2015.01.002

Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study

BACKGROUND The 2 Cohort randomised PrefHer trial examined the preferences of HER2+ve primary breast cancer patients for intravenous (IV) or subcutaneous (SC) delivery of trastuzumab via a Single Injectable Device (SID) or hand-held syringe (HHS). The novel approach and design of the study permitt…